226
1.
Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, A
amis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vas-
cular disease. Nat Rev Drug Discov.2006 Feb;5(2):123-32.
2.
Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell
M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang
T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yan-
copoulos GD, Rudge JS.VEGF-Trap: a VEGF blocker with
potent antitumor effects. Proc Natl Acad Sci U S A. 2002 Aug
20;99(17):11393-8. Epub 2002 Aug 12.
3.
Aflibercept, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF
Trap-Eye. Drugs in R & D. 9(4):261-269, July 1, 2008.
4.
Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-ad-
ministered vascular endothelial growth factor trap for treatment in
patients with choroidal neovascularization due to age-related mac-
ular degeneration. Ophthalmology. 2006;113:1522.e1-1522.e14.
5.
Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell
M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang
T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yan-
copoulos GD, Rudge JS.VEGF-Trap: a VEGF blocker with
potent antitumor effects. Proc Natl Acad Sci U S A. 2002 Aug
20;99(17):11393-8. Epub 2002 Aug 12.
6.
Aflibercept, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF
Trap-Eye. Drugs in R & D. 9(4):261-269, July 1, 2008.
7.
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investiga-
tion of Efficacy and Safety in Wet Age-Related Macular Degenera-
tion (AMD) (VIEW 2 )
00637377?term=vegf+trap+view&rank=2 Accessed in 28 March
2010.
8.
Citation
9.
Safety & Efficacy Study Evaluating the Combination of Beva-
siranib & Lucentis Therapy in Wet AMD (COBALT)
-
caltrials.gov/ct2/show/NCT00499590?term=bevasiranib+amd&r
ank=2 Accessed 29 March 2010.
10. Interim Results of the phase I, Open-Label, Dose-Escalation Study
of Intravitreal siRNA PF-04523655 in Patients With Choroidal
Neovascularization Secondary to Exudative Age-Related Macular
Degeneration: Safety, Tolerability, and Bioactivity, Quan Dong
Nguyen, MD, MSc, Presentation at ARVO 2009 Annual Meeting
in Fort Lauderdale.
11. Gomes Dos Santos AL, Bochot A, Fattal E. Intraocular delivery of
oligonucleotides. Curr Pharm Biotechnol 2005; 6: 7-15.
12. June 11, 2009 RNAi News;
admsg.aspx?msgid=25714154.
13.
-
sirna-rx-amd-poor-phase-ii-data.
14. A phase I, Safety, Tolerability and Pharmacokinetic Profile
of Intravitreous Injections of E10030 (Anti-PDGF Pegylat-
ed Aptamer) in Subjects With Neovascular Age-Related
Macular
Degeneration
/
NCT00569140?term=e10030&rank=1 Accessed in 26 March
2010.
15. Combined Inhibition of Platelet Derived (PDGF) and Vascular
Endothelial (VEGF) Growth Factors for the Treatment of Neo-
vascular Age-Related Macular Degeneration (NV-AMD) - Re-
sults of a phase I Study; D.S. Boyer, Presentation at ARVO 2009
Annual Meeting in Fort Lauderdale.
16. Citation
, accessed
in 28 March 2010.
17. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol.
2001;2(3):REVIEWS3005. Epub 2001 Mar 9. Review. PubMed
PMID: 11276432; PubMed Central PMCID: PMC138918.
18. Coutts JC, Gallagher JT. Receptors for fibroblast growth factors.
Immunol Cell Biol. 1995 Dec;73(6):584-9. Review.
19. Robinson CJ, Stringer SE. The splice variants of vascular en-
dothelial growth factor (VEGF) and their receptors. J Cell Sci.
2001 Mar;114(Pt 5):853-65. Review.
20. Larrivée B, Karsan A. Signaling pathways induced by vascu-
lar endothelial growth factor (review). Int J Mol Med. 2000
May;5(5):447-56. Review.
21. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endotheli-
al cell growth factor receptor signaling is sufficient to completely
prevent retinal neovascularization. Am J Pathol 2000;156:697-
707.
22. Safety and Efficacy of Oral PTK-787. in Patients With Subfoveal
Choroidal Neovascularization Secondary to Age-Related Macu-
lar Degeneration” (ADVANCE)
/
show/NCT00138632 Accessed in 28 March 2010.
23. Chen ZZ, et al. IOVS 2007;48: ARVO 2007 E-Abstract 1469.
24. Doukas J, Mahesh S, Umeda N, Kachi S, Akiyama H, Yokoi
K, Cao J, Chen Z, Dellamary L, Tam B, Racanelli-Layton A,
Hood J, Martin M, Noronha G, Soll R, Campochiaro PA. Topi-
cal administration of a multi-targeted kinase inhibitor suppresses
choroidal neovascularization and retinal edema. J Cell Physiol.
2008 Jul;216(1):29-37.
25. Palanki MS, Akiyama H, Campochiaro P, Cao J, Chow CP, Del-
lamary L, Doukas J, Fine R, Gritzen C, Hood JD, Hu S, Kachi
S, Kang X, Klebansky B, Kousba A, Lohse D, Mak CC, Martin
M, McPherson A, Pathak VP, Renick J, Soll R, Umeda N, Yee S,
Yokoi K, Zeng B, Zhu H, Noronha G. Development of prodrug
4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]
amino}-1,2,4-benzotria zin-7-yl)phenyl benzoate (TG100801): a
topically administered therapeutic candidate in clinical trials for
the treatment of age-related macular degeneration. J Med Chem.
2008 Mar 27;51(6):1546-59.
26. Open-Label, Pilot Study of TG100801 in Patients With Choroi-
dal Neovascularization Due to AMD.
/
ct2/show/NCT00509548. Accessed in 29 March 2010.
27. A Study to Evaluate the Pharmacodynamics, Safety, and Pharma-
cokinetics of Pazopanib Drops in Adult Subjects With Neovas-
cular AMD.
.
Accessed in 29 March 2010.
28. A Study Of The Safety And Efficacy Of AG-013,958 In Subjects
References:
